Development of Pharmacokinetics Model in Pregnancy Women and Fetus
Completed
- Conditions
- Preterm LaborPreterm Premature Rupture of Membrane (PPROM)
- Registration Number
- NCT01916330
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Pharmacokinetics analysis and development of pharmacokinetics model in pregnancy women and fetus
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 96
Inclusion Criteria
- 20 <= age < 50
- pregnant women who were administered intramuscular dexamethasone (ex) preterm labor)
- pregnant women who were administered PO clarithromycin (ex) PPROM/intrauterine infection or inflammation)
Exclusion Criteria
- who deny the study entrance
- who administered study drug before transfer to tertiary hospital
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analysis of drug concentration Day 1 after delivery drug (dexamethasone, clarithromycin)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence drug distribution in pregnant women and fetuses during preterm labor?
How does pharmacokinetics in pregnancy affect the efficacy of tocolytic agents for preterm labor management?
What biomarkers are associated with preterm premature rupture of membranes (PPROM) and fetal drug exposure risks?
Are there adverse events linked to pharmacokinetic changes in maternal-fetal drug transfer during pregnancy?
What combination therapies show promise for managing PPROM and preterm labor alongside pharmacokinetic modeling?
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital🇰🇷Seoul, Korea, Republic of